RU2020103424A - Схема введения с 21-дневными интервалами слитых белков, содержащих фактор ix и альбумин человека, для профилактического лечения гемофилии и способы такого лечения - Google Patents

Схема введения с 21-дневными интервалами слитых белков, содержащих фактор ix и альбумин человека, для профилактического лечения гемофилии и способы такого лечения Download PDF

Info

Publication number
RU2020103424A
RU2020103424A RU2020103424A RU2020103424A RU2020103424A RU 2020103424 A RU2020103424 A RU 2020103424A RU 2020103424 A RU2020103424 A RU 2020103424A RU 2020103424 A RU2020103424 A RU 2020103424A RU 2020103424 A RU2020103424 A RU 2020103424A
Authority
RU
Russia
Prior art keywords
use according
paragraphs
fusion protein
seq
per year
Prior art date
Application number
RU2020103424A
Other languages
English (en)
Russian (ru)
Other versions
RU2020103424A3 (https=
Inventor
Яньянь ЛИ
Дебра БЕНСЕН-КЕННЕДИ
Ирис ДЖЕЙКОБС
Кристин ВОИГТ
Original Assignee
Цсл Беринг Ленгнау Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Цсл Беринг Ленгнау Аг filed Critical Цсл Беринг Ленгнау Аг
Publication of RU2020103424A publication Critical patent/RU2020103424A/ru
Publication of RU2020103424A3 publication Critical patent/RU2020103424A3/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/644Coagulation factor IXa (3.4.21.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4846Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21022Coagulation factor IXa (3.4.21.22)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RU2020103424A 2017-06-29 2018-06-29 Схема введения с 21-дневными интервалами слитых белков, содержащих фактор ix и альбумин человека, для профилактического лечения гемофилии и способы такого лечения RU2020103424A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762526377P 2017-06-29 2017-06-29
US62/526377 2017-06-29
PCT/EP2018/067523 WO2019002532A1 (en) 2017-06-29 2018-06-29 21-DAY FUSION PROTEIN DRAFTING COMPRISING IX FACTOR AND HUMAN ALBUMIN FOR THE PROPHYLACTIC TREATMENT OF HEMOPHILIA AND ASSOCIATED METHODS

Publications (2)

Publication Number Publication Date
RU2020103424A true RU2020103424A (ru) 2021-07-29
RU2020103424A3 RU2020103424A3 (https=) 2021-11-12

Family

ID=62815032

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2020103424A RU2020103424A (ru) 2017-06-29 2018-06-29 Схема введения с 21-дневными интервалами слитых белков, содержащих фактор ix и альбумин человека, для профилактического лечения гемофилии и способы такого лечения

Country Status (15)

Country Link
US (1) US20200115436A1 (https=)
EP (1) EP3645034B1 (https=)
JP (1) JP2020525498A (https=)
KR (1) KR102597725B1 (https=)
CN (1) CN110799209A (https=)
AU (1) AU2018294517B2 (https=)
CA (1) CA3068360A1 (https=)
DK (1) DK3645034T5 (https=)
ES (1) ES2963665T3 (https=)
IL (1) IL271160B2 (https=)
MX (1) MX2019014651A (https=)
PL (1) PL3645034T3 (https=)
RU (1) RU2020103424A (https=)
SG (1) SG10202111032PA (https=)
WO (1) WO2019002532A1 (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2206720A1 (en) 2000-04-12 2010-07-14 Human Genome Sciences, Inc. Albumin fusion proteins
US7939632B2 (en) 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
KR20120061898A (ko) * 2009-08-20 2012-06-13 체에스엘 베링 게엠베하 출혈성 장애의 치료요법 및 예방 치료에 있어서의 비정맥내 투여를 위한 알부민 융합 응고 인자
UA126265C2 (uk) 2010-07-09 2022-09-14 Байовератів Терапьютікс Інк. Поліпептид фактора іх і спосіб його застосування
TWI750197B (zh) * 2012-09-25 2021-12-21 美商百歐維拉提夫治療公司 Fix多肽的應用
BR112016013577A2 (pt) * 2013-12-23 2017-10-03 Csl Ltd Proteínas de fusão, seu uso e composição farmacêutica
WO2015154139A1 (en) * 2014-04-11 2015-10-15 Csl Limited Half-life extended factor fviia protein for prevention and treatment of bleeding and dosing regimens therefor

Also Published As

Publication number Publication date
EP3645034A1 (en) 2020-05-06
JP2020525498A (ja) 2020-08-27
RU2020103424A3 (https=) 2021-11-12
CN110799209A (zh) 2020-02-14
ES2963665T3 (es) 2024-04-01
SG10202111032PA (en) 2021-11-29
WO2019002532A1 (en) 2019-01-03
EP3645034B1 (en) 2023-08-30
US20200115436A1 (en) 2020-04-16
AU2018294517A1 (en) 2020-01-30
PL3645034T3 (pl) 2024-09-02
IL271160A (en) 2020-01-30
DK3645034T3 (da) 2023-11-20
IL271160B1 (en) 2025-01-01
KR20200019749A (ko) 2020-02-24
MX2019014651A (es) 2020-02-07
KR102597725B1 (ko) 2023-11-06
AU2018294517B2 (en) 2024-09-26
CA3068360A1 (en) 2019-01-03
DK3645034T5 (da) 2024-08-26
IL271160B2 (en) 2025-05-01

Similar Documents

Publication Publication Date Title
US20240052060A1 (en) Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
Pusateri et al. Dried plasma: state of the science and recent developments
Pasi et al. Long‐term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: results from the B‐YOND extension study
Courter et al. Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients
EA032336B1 (ru) Стабильная водная иммуноглобулиновая композиция и способ стабилизации иммуноглобулиновой композиции
MX2017012506A (es) Composicion farmaceutica para la prevencion y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteina de fusion en la cual el peptido que penetra el tejido y la preparacion del factor de crecimiento endotelial antivascular se fusionan.
JP2012529440A (ja) 病原体感染を予防又は治療するためのインターフェロン投与
RU2016129911A (ru) Слитые белки, содержащие фактор ix, для профилактического лечения больных гемофилией и способы его осуществления
Bisgin et al. Current update on severe acute respiratory syndrome coronavirus 2 vaccine development with a special emphasis on gene therapy viral vector design and construction for vaccination
Morfini et al. Prevalence of infection with the hepatitis C virus among Italian hemophiliacs before and after the introduction of virally inactivated clotting factor concentrates: a retrospective evaluation
Hogan et al. α1-Antitrypsin: key player or bystander in acute respiratory distress syndrome?
KR20200076705A (ko) 둘라글루티드를 함유하는 조성물 및 사용 방법
KR20250024800A (ko) A형 및 b형 혈우병의 치료를 위한 피투시란
RU2020103424A (ru) Схема введения с 21-дневными интервалами слитых белков, содержащих фактор ix и альбумин человека, для профилактического лечения гемофилии и способы такого лечения
US11554156B2 (en) Pharmaceutical formulations of C1 esterase inhibitor
CN102065844A (zh) 干燥转谷氨酰胺酶组合物
Spira et al. Safety and efficacy of a long-acting liposomal formulation of plasma-derived factor VIII in haemophilia A patients.
Dunn et al. Current issues in prophylactic therapy for persons with hemophilia
JP2020525498A5 (https=)
JP2019524089A5 (https=)
RU2004117534A (ru) Фармацевтическая композиция, содержащая полипептиды фактора vii и полипептиды фактора v
Escobar Treatment on demand–in vivo dose finding studies
Leon et al. The Role of Selected Adjuncts in the Management of the Bleeding Trauma Patient: Calcium and Vasopressin
Gradman et al. Vaccination: a novel strategy for inhibiting the renin-angiotensin-aldosterone system
RU2016144159A (ru) Белок-фактор fviia с увеличенным периодом полужизни для профилактики и лечения кровотечения, и его режимы дозирования